BioVector® mEER 小鼠口咽鳞状细胞癌细胞系 / mEER Mouse Oropharyngeal Squamous Cell Carcinoma Cell Line

通用定义 / General Definition:

BioVector® mEER (Mouse Epithelial Endocervical Ras) 是一种经由人乳头瘤病毒 16 型 (HPV16) 的 E6 和 E7 癌蛋白以及活化的 H-Ras 基因稳定转染而成的 C57BL/6 小鼠细胞系。它是目前研究 HPV 阳性头颈部鳞状细胞癌 (HNSCC) 最具代表性的同系免疫模型。该细胞系不仅在遗传背景上模拟了人类 HPV 相关的口咽癌，还能在免疫健全的小鼠体内成瘤，广泛用于肿瘤免疫治疗和放疗响应研究。

BioVector® mEER is a C57BL/6 mouse cell line stably transfected with Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins, along with activated H-Ras. It is the gold-standard syngeneic model for studying HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). By mimicking the genetic landscape of human HPV-related head and neck cancers, it enables the study of tumor growth in immunocompetent environments, making it essential for research in immunotherapy and radiotherapy responses.

BioVector® mEER 细胞系技术说明书 (Cell Line Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® mEER 小鼠口咽鳞状细胞癌细胞

• 细胞来源： 小鼠 (C57BL/6)

• 组织来源： 宫颈上皮（经改造模拟口咽癌）

• 生长特性： 贴壁生长

• 细胞形态： 上皮细胞样

2. 培养条件

• 基础培养基： BioVector® DMEM/F12 培养基 (1:1)

• 血清添加： 10% BioVector® 胎牛血清 (FBS)

• 培养环境： 37°C，5% $CO_2$，饱和湿度

• 额外建议： 某些实验方案可能需要添加特定生长因子（如胰岛素或 $EGF$），视具体实验目的而定。

3. 细胞应用

• HPV 阳性头颈部鳞状细胞癌 (HNSCC) 的发病机制研究。

• 评估针对 HPV 抗原的免疫检查点抑制剂或癌症疫苗。

• 肿瘤微环境中的免疫浸润与逃逸机制研究。

4. 注意事项

• 生物安全性： 由于含有 HPV16 基因组片段，操作时需严格遵循生物安全 2 级 (BSL-2) 标准。

• 模型验证： 在植入小鼠体内前，建议通过 PCR 验证 E6/E7 的表达以确保模型稳定性。

English Datasheet

1. General Product Information

• Product Name: BioVector® mEER Mouse Oropharyngeal Squamous Cell Carcinoma Cell Line

• Organism: Mouse (C57BL/6)

• Tissue Source: Cervical Epithelium (Engineered to model OPSCC)

• Growth Properties: Adherent

• Morphology: Epithelial-like

2. Culture Conditions

• Basal Medium: BioVector® DMEM/F12 Medium (1:1)

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37°C, 5% $CO_2$, Saturated Humidity

• Additional Supplement: Specific protocols may require supplements like Insulin or $EGF$ depending on downstream applications.

3. Applications

• Pathogenesis studies of HPV-positive Head and Neck Squamous Cell Carcinoma (HNSCC).

• Evaluation of immune checkpoint inhibitors or cancer vaccines targeting HPV antigens.

• Research on immune infiltration and escape mechanisms within the tumor microenvironment.

4. Key Usage Notes

• Biosafety: As the cell line contains HPV16 E6/E7 sequences, it must be handled under Biosafety Level 2 (BSL-2) protocols.

• Validation: It is recommended to verify E6/E7 expression via PCR before in vivo implantation to ensure model consistency.

Note: For optimal results and to maintain the specific oncogenic expression profile, the use of BioVector® DMEM/F12 Medium and BioVector® Fetal Bovine Serum is highly recommended.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net